Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Debt: 2020

Historic Non-Current Debt for Foghorn Therapeutics (FHTX) over the last 1 years, with Dec 2020 value amounting to $19.7 million.

  • Foghorn Therapeutics' Non-Current Debt was N/A to $19.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $19.7 million, marking a year-over-year change of. This contributed to the annual value of $19.7 million for FY2020, which is N/A change from last year.
  • Per Foghorn Therapeutics' latest filing, its Non-Current Debt stood at $19.7 million for FY2020.
  • Foghorn Therapeutics' Non-Current Debt's 5-year high stood at $19.7 million during FY2020, with a 5-year trough of $19.7 million in FY2020.
  • Moreover, its 1-year median value for Non-Current Debt was $19.7 million (2020), whereas its average is $19.7 million.